October 5, 2020 10:24 AM EDTUpdated 01:28 PM
News Briefing

News brief­ing: Kro­nos Bio sets terms for IPO, flirt­ing with bil­lion-dol­lar uni­corn val­u­a­tion; Corvus col­labs with spin­out, un­veils pos­i­tive Covid-19 da­ta

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Kro­nos Bio an­nounced it’s look­ing to raise more than $200 mil­lion in its jump on­to Nas­daq, flirt­ing with a bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

A service from the Financial Times